ICER MIDWEST CEPAC WORKS TO KEEP UP WITH WELL-INFORMED NASH PATIENT ADVOCATES
May 01, 2023 17:36 ET
|
Global Liver Institute
Washington, DC, May 01, 2023 (GLOBE NEWSWIRE) -- On Friday, the Institute for Clinical and Economic Review (ICER) held a public hearing to review its draft assessment of Resmetirom and Obeticholic...
PATIENT GROUPS DECLARE ICER REVIEW OF NASH MEDICATIONS CAUSES MORE UNCERTAINTY AND CONTROVERSIES THAN IT RESOLVES
April 28, 2023 12:22 ET
|
Global Liver Institute
Washington, DC, April 28, 2023 (GLOBE NEWSWIRE) -- Today, the Institute for Clinical and Economic Review (ICER) will hold a public hearing on its draft assessment of Resmetirom and Obeticholic Acid...
Global Urinalysis Market Expected to Garner $4,776.9 Million in the 2021-2028 Timeframe, Growing at 6.3% CAGR [170-Pages] | Released by Research Dive
January 25, 2023 09:00 ET
|
Research Dive
New York, USA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Research Dive, the global urinalysis market is predicted to rise at a tremendous CAGR of 6.3%, thereby...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
October 31, 2022 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting new data from its hepatitis B virus (HBV) clinical program...
Global Liver Disease Treatment Market Anticipated to Garner $32,028.5 Million, Growing with 11.7% CAGR in the 2021–2028 Timeframe [240-Pages] | Wrap up by Research Dive
October 12, 2022 08:59 ET
|
Research Dive
New York, USA, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Research Dive has published a new report on the global liver disease treatment market. According to the report, the global market is projected to...
Livivos, Inc. Announces Award of NIH Grant for Its LiverScope® Device
October 04, 2022 06:15 ET
|
Livivos
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Livivos, Inc., a San Diego-based biomedical device technology startup, announced today that it had received a $300,000 Phase I Small Business Innovation...
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
June 16, 2022 16:00 ET
|
INVENTIVA
Update on Inventiva’s NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven FrancqueUpdate on the current NASH landscape...
Inventiva organise un webcast avec des leaders d’opinion à l’occasion de l’EASL International Liver Congress™ 2022
June 16, 2022 16:00 ET
|
INVENTIVA
Point sur l’étude clinique de Phase III NATiV3 d'Inventiva évaluant lanifibranor chez les patients atteints de NASH et de fibrose (stade F2/F3) non cirrhotique par le Prof. Sven FrancquePoint sur le...
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
June 09, 2022 16:00 ET
|
INVENTIVA
Three poster presentations showing the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH fibrosis independent of weight gain observed.the...
Inventiva annonce la présentation de trois abstracts scientifiques lors de l’EASL International Liver Congress™ 2022
June 09, 2022 16:00 ET
|
INVENTIVA
Trois présentations par poster démontrant : les effets bénéfiques de lanifibranor sur les marqueurs de la santé cardiométabolique chez les patients atteints de NASH avec fibrose non cirrhotique,...